Nephrocare Health IPO Listing: Nephrocare Health Services, which runs the largest dialysis chain in India and Asia, made a stellar debut in the domestic stock market today. Its IPO was oversubscribed more than 14 times. Shares were issued in the IPO at a price of ₹460 per share.
Today the stock was listed at ₹ 491.70 on BSE and ₹ 490.00 on NSE, giving IPO investors a listing gain of about 7%. The share price increased further after listing.
It rose to ₹498.70 on BSE (Nephrocare Health share price), which means IPO investors are now at a profit of 8.41%. Employees benefited even more as they received each share at a discount of ₹41.
How will the money from Nephrocare Health IPO be used?
Nephrocare Health’s ₹871.39 crore IPO was open for subscription from December 10 to 12. The IPO received an overwhelming response from investors and was oversubscribed by a total of 14.08 times.
The reserved portion for Qualified Institutional Buyers (QIBs) was subscribed 26.82 times (except anchor investors), Non-Institutional Investors (NIIs) portion was subscribed 24.77 times, Retail Investors portion was subscribed 2.36 times and Employees portion was subscribed 2.81 times. New shares worth ₹353.75 crore were issued under this IPO.
Additionally, 1,12,53,102 shares with face value of ₹2 were sold through the offer for sale window. The money received from the offer for sale went to the selling shareholders. Of the funds raised from the new shares, ₹129.11 crore will be used to open new dialysis clinics, ₹136.00 crore will be used to reduce debt and the remaining funds will be used for general corporate purposes. About Nephrocare Health
Established in 2010, Nephrocare Health Services provides dialysis care through its large network in India and internationally. Its services include diagnosis, hemodialysis, home and mobile dialysis, and wellness programs. As of September 2025, it runs 519 clinics, of which 59 are in the Philippines, Uzbekistan and Nepal.
Its dialysis clinic in Uzbekistan is one of the largest clinics in the world. In India, its clinics are spread across 21 states and 4 union territories. 77.53% of its clinics are in Tier 2 and Tier 3 cities. The company has strategic partnerships with leading hospital chains such as Max Super Specialty Hospital, Fortis Escorts Hospitals and Care Hospitals.
The financial position of the company has continuously strengthened. After suffering a net loss of ₹11.79 crore in FY2023, it reached a net profit of ₹35.13 crore in FY2024, which increased to ₹67.10 crore in FY2025. During this period, the company’s total income grew to ₹769.92 crore at a compound annual growth rate (CAGR) of more than 31%.
In the current financial year 2026, for the first six months (April-September 2025), the company has already achieved a net profit of ₹14.23 crore and a total income of ₹483.97 crore. As of the end of the September 2025 quarter, the company had total debt of ₹207.04 crore, while its reserves and surplus stood at ₹704.14 crore.
Comments are closed.